World

Novartis gets European nod to gene therapy for retinal disease

Reuters | | Updated on: Nov 23, 2018
image caption

Novartis on Friday said it had received European Union approval for its Luxturna gene therapy to restore sight to people with a rare retinal disease.

Luxturna is a one-time treatment for children and adults who have suffered impaired vision from an early age due to mutations in both copies of the RPE65 gene. Such mutations, which can lead to blindness, affect roughly 1 in 200,000 people, according to Novartis.

The authorisation is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway, Novartis said. Luxturna was developed and is commercialized in the United States by Spark Therapeutics.

Published on November 23, 2018

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

COMMENTS
This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you